Sept. 5, 8 a.m. –5 p.m. | Sept. 6, 8 a.m. – 3:30 p.m.
Alessandra Cesano, MD, PhD – ESSA Pharma Inc.
Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
In the wake of the 2017 U.S. Food and Drug Administration approvals for Chimeric Antigen Receptor (CAR) T cell therapies for the treatment of patients with lymphoma and leukemia, adoptive cellular therapies have rapidly become a focal point for stakeholders across the field of cancer immunotherapy.
As this treatment modality has displayed unprecedented patient response and offers significant curative potential for cancer patients across the globe, SITC is proud to host an Adoptive Cellular Therapies Workshop to support both continued momentum and clinical advancement.
This two-day workshop will bring together cancer immunotherapy experts to discuss and address challenges concerning the use and development of adoptive cellular therapies for the treatment of cancer patients.
Throughout seven didactic sessions and participation in collaborative working groups, attendees will discuss a number of topics, including:
- Development of novel strategies to improve the overall risk/benefit profile for adoptive cellular therapies
- Clinical development and regulatory challenges
- Real world hurdles that impact scalability and patient access
It is anticipated that the efforts of this workshop, and the resulting manuscript, will help fuel innovative collaborative efforts as well as the dissemination of knowledge throughout the field.#ClinicalTrials